Liu Yanyan

[Expert Profile] Liu Yanyan, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in lymphoma in China, working at the Cancer Hospital of the Chinese Academy of Medical Sciences. She has long been dedicated to the clinical diagnosis, treatment, and scientific research of difficult lymphomas such as mantle cell lymphoma and relapsed/refractory Hodgkin lymphoma, and is an important expert in lymphoma diagnosis and treatment in China.

[Education & Career] Professor Liu Yanyan graduated from a renowned medical university, completed systematic clinical training at the Cancer Hospital of the Chinese Academy of Medical Sciences, and has long been engaged in clinical and research work on lymphoma. She has held academic positions in organizations such as the Lymphoma Professional Committee of the Chinese Anti-Cancer Association, and has presided over grants from the National Natural Science Foundation of China and Beijing municipal research programs, accumulating extensive experience in precise lymphoma diagnosis and treatment.

[Areas of Expertise] Professor Liu specializes in standardized diagnosis and treatment of mantle cell lymphoma, Hodgkin lymphoma, diffuse large B-cell lymphoma, and various lymphomas, with particularly extensive experience in comprehensive treatment of relapsed/refractory lymphoma. She is proficient in precise pathological subtyping of lymphoma, PET-CT staging assessment, chemotherapy combined with immunotherapy and targeted therapy, and high-dose therapy supported by autologous stem cell transplantation. She excels at developing individualized salvage treatment plans for "refractory lymphoma patients who fail first-line therapy," helping numerous patients achieve second remission and long-term survival.

[Academic Achievements & Industry Contributions] Professor Liu has led a series of clinical studies on relapsed/refractory lymphoma, systematically evaluating the application value of novel targeted drugs, immunotherapy, and cellular therapy in refractory lymphoma, with findings published in authoritative domestic and international journals. She has participated in the development of Chinese lymphoma diagnosis and treatment guidelines and expert consensus statements, actively promoted standardized lymphoma diagnosis and treatment and the MDT (multidisciplinary team) model, and led multiple national multi-center clinical trials, making important contributions to improving the treatment level of refractory lymphoma in China.

[Clinical Practice & Outstanding Contributions] Professor Liu has long held dedicated lymphoma clinics, cumulatively treating tens of thousands of patients with various lymphomas, including many relapsed/refractory patients who traveled across multiple regions seeking care. Leading her team, she has secured life opportunities for countless refractory lymphoma patients who were "given up as hopeless." She is sincere and responsible with patients, insisting on long-term follow-up and whole-course care, and is deeply trusted by patients and respected by peers alike. She is an outstanding expert in the field of precise lymphoma diagnosis and treatment.

[Honors & Reputation] Professor Liu Yanyan serves as director of relevant departments at the Cancer Hospital of the Chinese Academy of Medical Sciences, among other academic positions. She has presided over grants from the National Natural Science Foundation of China and major provincial and ministerial projects, and is a senior expert in the field of lymphoma in China. She has profound expertise in standardized diagnosis, treatment, and innovative therapy of mantle cell lymphoma and relapsed/refractory Hodgkin lymphoma. She has led research on precise lymphoma diagnosis and individualized treatment, promoted standardized application of targeted therapy, immunotherapy, CAR-T, and other new technologies, and participated in the development of multiple lymphoma diagnosis and treatment guidelines. For decades on the clinical front lines, she has helped numerous relapsed/refractory lymphoma patients gain new treatment opportunities and prolonged survival, and is deeply trusted by patients and respected by peers alike.